Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 40, 2014, Pages 14494-14499

  Kim, Seungsoo ^a,c   Lieberman, Tami D ^a   Kishony, Roy ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; SULFAMETHOXAZOLE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CONFERENCE PAPER; CROSS RESISTANCE; DRUG THERAPY; EVOLUTION; GENE MUTATION; INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; THERAPY; WILD TYPE; BACTERIAL GENOME; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; HUMAN; MICROBIOLOGY; MOLECULAR EVOLUTION; MUTATION; MUTATION RATE; PROCEDURES; STAPHYLOCOCCAL INFECTIONS; TIME FACTOR;

ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY; DRUG THERAPY, COMBINATION; EVOLUTION, MOLECULAR; GENOME, BACTERIAL; HUMANS; MUTATION; MUTATION RATE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 84925934394     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1409800111     Document Type: Article

References (45)

1. Taubes G (2008) The bacteria fight back. Science 321(5887):356-361.
2. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: Causes, challenges and responses. Nat Med 10(12, Suppl):S122-S129.
3. Lipsitch M, Bergstrom CT, Levin BR (2000) The epidemiology of antibiotic resistance in hospitals: Paradoxes and prescriptions. Proc Natl Acad Sci USA 97(4):1938-1943.
4. US Department of Health and Human Services (2013) Antibiotic Resistance Threats in the United States 2013 (Centers for Disease Control and Prevention, Atlanta).
5. Lieberman TD, et al. (2011) Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes. Nat Genet 43(12):1275-1280.
6. Musher DM, et al. (2002) Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 346(8):630-631.
7. Lipsitch M, Levin BR (1997) The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 41(2):363-373.
8. Stone NR, et al. (2011) Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis. J Antimicrob Chemother 66(11):2677-2678.
9. Bush K, et al. (2011) Tackling antibiotic resistance. Nat Rev Microbiol 9(12):894-896.
10. Joshi JM (2011) Tuberculosis chemotherapy in the 21 century: Back to the basics. Lung India 28(3):193-200.
11. Mouton JW (1999) Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 27(Suppl 2):S24-S28.
12. Michel JB, Yeh PJ, Chait R, Moellering RC, Jr, Kishony R (2008) Drug interactions modulate the potential for evolution of resistance. Proc Natl Acad Sci USA 105(39): 14918-14923.
13. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R (2008) Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci USA 105(37):13977-13981.
14. Gressel J, Segel L (1990) Negative cross resistance; a possible key to atrazine resistance management: A cell for whole plant data. Z Naturforsch C 45(5):470-473.
15. Sanders CC, Sanders WE, Jr, Goering RV, Werner V (1984) Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother 26(6):797-801.
16. Imamovic L, Sommer MOA (2013) Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med 5(204):ra132.
17. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R (2009) Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 7(6):460-466.
18. Acar JF (2000) Antibiotic synergy and antagonism. Med Clin North Am 84(6):1391-1406.
19. Tamma PD, Cosgrove SE, Maragakis LL (2012) Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 25(3):450-470.
20. Safdar N, Handelsman J, Maki DG (2004) Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-Analysis. Lancet Infect Dis 4(8):519-527.
21. Chow JW, Yu VL (1999) Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: A commentary. Int J Antimicrob Agents 11(1):7-12.
22. Bal AM, Kumar A, Gould IM (2010) Antibiotic heterogeneity: From concept to practice. Ann N Y Acad Sci 1213(1):81-91.
23. Beardmore RE, Pena-Miller R (2010) Antibiotic cycling versus mixing: The difficulty of using mathematical models to definitively quantify their relative merits. Math Biosci Eng 7(4):923-933.
24. Brown EM, Nathwani D (2005) Antibiotic cycling or rotation: A systematic review of the evidence of efficacy. J Antimicrob Chemother 55(1):6-9.
25. Bergstrom CT, Lo M, Lipsitch M (2004) Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci USA 101(36):13285-13290.
26. Bonhoeffer S, Lipsitch M, Levin BR (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 94(22):12106-12111.
27. Toprak E, et al. (2012) Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat Genet 44(1):101-105.
28. Huovinen P, Sundström L, Swedberg G, Sköld O (1995) Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother 39(2):279-289.
29. Fourmy D, Recht MI, Puglisi JD (1998) Binding of neomycin-class aminoglycoside antibiotics to the A-site of 16 S rRNA. J Mol Biol 277(2):347-362.
30. Walsh C (2003) Antibiotics: Actions, Origins, Resistance (ASM, Washington, DC).
31. Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339(8):520-532.
32. Raviglione MC, et al. (1990) Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother 34(11):2050-2054.
33. Pappas G, Athanasoulia AP, Matthaiou DK, Falagas ME (2009) Trimethoprim-sulfamethoxazole for methicillin-resistant Staphylococcus aureus: A forgotten alternative? J Chemother 21(2):115-126.
34. Suzuki Y, et al. (1998) Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 36(5):1220-1225.
35. Jacoby GA (2005) Mechanisms of resistance to quinolones. Clin Infect Dis 41(Suppl 2): S120-S126.
36. Miyazaki E, Chen JM, Ko C, Bishai WR (1999) The Staphylococcus aureus rsbW (orf159) gene encodes an anti-sigma factor of SigB. J Bacteriol 181(9):2846-2851.
37. Kröger E, Witt E, Ohlmeier S, Hanschke R, Hecker M (2000) The clp proteases of Bacillus subtilis are directly involved in degradation of misfolded proteins. J Bacteriol 182(11):3259-3265.
38. Lázár V, et al. (2013) Bacterial evolution of antibiotic hypersensitivity. Mol Syst Biol 9(1):700.
39. Szybalski W, Bryson V (1952) Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J Bacteriol 64(4): 489-499.
40. Oz T, et al. (2014) Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. Mol Biol Evol 31(9): 2387-2401.
41. Weinreich DM, Delaney NF, Depristo MA, Hartl DL (2006) Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312(5770):111-114.
42. Trindade S, et al. (2009) Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet 5(7):e1000578.
43. MacKenzie FM, Gould IM (1993) The post-Antibiotic effect. J Antimicrob Chemother 32(4):519-537.
44. Gillespie SH, Basu S, Dickens AL, O'Sullivan DM, McHugh TD (2005) Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J Antimicrob Chemother 56(2):344-348.
45. Nair D, et al. (2011) Whole-genome sequencing of Staphylococcus aureus strain RN4220, a key laboratory strain used in virulence research, identifies mutations that affect not only virulence factors but also the fitness of the strain. J Bacteriol 193(9): 2332-2335.